BioPharma Resources

Company · ONC

BeOne Medicines (BeiGene)

Includes drugs filed under related and acquired sponsor names. Trials are searched under: BeiGene; BeOne Medicines.

Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov

NDAs and BLAs

6

5 still marketed

Novel approvals

3

Approvals since 2021

21

Originals and new uses

Phase 3 trials

37

Registered, any status

Trials by phase

All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.

Recent approvals

Originals and efficacy supplements, newest first.

  • Tevimbra new use Priority reviewOrphanAug 25, 2026
  • Beqalzi approved NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanMay 13, 2026
  • Tevimbra new use OrphanDec 9, 2025
  • Tevimbra new use OrphanDec 9, 2025
  • Tevimbra new use OrphanDec 9, 2025
  • Brukinsa approved Accelerated approvalOrphanJun 10, 2025
  • Brukinsa approved OrphanJun 10, 2025
  • Tevimbra new use OrphanApr 22, 2025
  • Tevimbra new use OrphanApr 22, 2025
  • Tevimbra new use OrphanApr 22, 2025

Drugs in development (12)

Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.

Open in pipeline

Recruiting Phase 3 trials

Largest first.

Marketed drugs (5)

Newest FDA action first.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.